Reported 1 day ago
Roche announced it is finalizing its $1.5 billion acquisition of U.S. biopharma company Poseida Therapeutics, specializing in advanced immune cell therapies for blood cancer. The deal involves Roche purchasing approximately 66% of Poseida's shares at $9 each, with additional contingent payments. Poseida will operate as a wholly-owned subsidiary, enhancing Roche's portfolio with innovative CAR-T therapies targeting various cancers and autoimmune diseases.
Source: YAHOO